Minnesota based, St. Jude Medical, Inc., a global medical device company, has implanted Allure Quadra Cardiac Resynchronization Therapy Pacemaker (CRT-P) in India. The first-to-market quadripolar pacemaker system offers more pacing options for patients with heart failure (HF) and is the first company to bring quadripolar lead technology to India.
Quadripolar leads allow for increased implant efficiencies, which clinical data indicates can result in fewer surgical revisions. Broad clinical evidence on the advantages of the St Jude Medical quadripolar technology has been documented in more than 100 publications worldwide.
Explaining how quadripolar technology works, Dr Anil Saxena, Fortis Escorts Hospital, New Delhi, says, “Historically, pacing systems that treat heart failure included a lead with only one electrode in the heart. Later, these were replaced by leads with two electrodes. Nearly 40 per cent of patients do not effectively benefit from traditional pacing due to potential complications of cardiac resynchronization therapy such as high pacing thresholds, dislocation of the lead and occasional stimulation of the phrenic nerve, all of which require repeat surgeries. The new quadripolar technology has four electrodes and ten programmable pacing configurations, allowing electrophysiologists to more effectively manage their patients with greater flexibility and improved patient outcomes.”
Approximately one in 10 patients who receive a bipolar CRT system has complications that could require additional surgery. Quadripolar technology from St. Jude Medical allows for additional pacing configurations that provide physicians with options not available on traditional bipolar systems. These additional options help manage common pacing complications without exposing the patient to additional surgeries for lead repositioning.
“Our new Allure Quadra pacemaker allows us to expand the proven clinical benefits of quadripolar technology to a new patient population,” said Kaustav Banerjee, managing director of St. Jude Medical India. “We believe these benefits result in a cost-effective solution that elevates the standard of care for heart failure patients in India who need cardiac resynchronization therapy.”
The ASSERT, or ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial, was designed to determine whether the detection of arrhythmias using pacemaker-based diagnostics predicts an increased risk of stroke in elderly, hypertensive patients without any history of atrial fibrillation (AF). Results found that pacemaker patients who have no history of atrial tachycardia (AT) or atrial fibrillation (AF), but have device-detected arrhythmias, are approximately 2.5 times more likely to have a stroke than patients who do not have device-detected arrhythmias.
Additionally, the Allure CRT-P device improves HF management through timely access to vital diagnostic data that provides earlier insight into disease progression. The Allure Quadra CRT-P integrates best-in-class quadripolar technology with multiple pacing configurations and features designed to help physicians address the dynamic challenges of HF by optimizing the quadripolar system at implant and follow-up.